Long-term follow-up data from the phase III KATHERINE study in people with HER2-positive early-stage breast cancer who have residual invasive disease following neoadjuvant treatment showed that a statistically significant and clinically meaningful improvement in overall survival, a secondary endpoint, was observed with adjuvant Kadcyla (ado-trastuzumab emtansine) compared to Herceptin (trastuzumab).
Reduced screening rates and a higher prevalence of triple-negative breast cancer are driving elevated rates of advanced breast cancer in a geographic hotspot in Wilmington, Delaware, according to findings by researchers at ChristianaCare’s Cawley Center for Translational Cancer Research at the Helen F. Graham Cancer Center & Research Institute.
